75 related articles for article (PubMed ID: 8586407)
41. Pentoxyfilline treatment does not influence the plasma levels of IL-2 and sIL-2R in limited scleroderma patients.
Chibowska M; Krasowska D; Weglarz J
Med Sci Monit; 2001; 7(2):282-8. PubMed ID: 11257736
[TBL] [Abstract][Full Text] [Related]
42. [The serum level of the secreted interleukin 2 receptor (sIL-2R): a lymphocyte activity parameter in sarcoidosis].
Müller-Quernheim J; Strausz J; Ferlinz R
Pneumologie; 1990 Feb; 44 Suppl 1():213-4. PubMed ID: 2367367
[TBL] [Abstract][Full Text] [Related]
43. Immune activation in cervical neoplasia: cross-sectional association between plasma soluble interleukin 2 receptor levels and disease.
Hildesheim A; Schiffman MH; Tsukui T; Swanson CA; Lucci J; Scott DR; Glass AG; Rush BB; Lorincz AT; Corrigan A; Burk RD; Helgesen K; Houghten RA; Sherman ME; Kurman RJ; Berzofsky JA; Kramer TR
Cancer Epidemiol Biomarkers Prev; 1997 Oct; 6(10):807-13. PubMed ID: 9332763
[TBL] [Abstract][Full Text] [Related]
44. Serum levels of interleukins 2, 6 and 8, soluble interleukin-2 receptor and intercellular adhesion molecule-1 during treatment with interleukin-2 plus interferon-alfa.
Vuoristo MS; Kellokumpu-Lehtinen P; Laine S; Soppi E
Immunopharmacol Immunotoxicol; 1996 Aug; 18(3):337-54. PubMed ID: 8872489
[TBL] [Abstract][Full Text] [Related]
45. IL-10 and sIL-2R serum levels as possible peripheral blood prognostic markers in the passage from adenoma to colorectal cancer.
Berghella AM; Pellegrini P; Del Beato T; Adorno D; Casciani CU
Cancer Biother Radiopharm; 1997 Aug; 12(4):265-72. PubMed ID: 10851474
[TBL] [Abstract][Full Text] [Related]
46. Interleukin 2-dependent immunoregulatory function in hemodialysis patients with chronic hepatitis C.
Garyfallos A; Raptopoulou-Gigi M; Orphanou H; Spaia S; Petridou P; Vayionas G
J Investig Allergol Clin Immunol; 1995; 5(5):255-8. PubMed ID: 8574431
[TBL] [Abstract][Full Text] [Related]
47. Soluble interleukin-2 receptor levels correlated with positive symptoms during quetiapine treatment in schizophrenia-spectrum disorders.
Igue R; Potvin S; Bah R; Stip E; Bouchard RH; Lipp O; Gendron A; Kouassi E
Prog Neuropsychopharmacol Biol Psychiatry; 2011 Aug; 35(7):1695-8. PubMed ID: 21627977
[TBL] [Abstract][Full Text] [Related]
48. Serum levels of interleukin-2 in cancer patients: preliminary considerations.
Lissoni P; Viviani S; Santoro A; Barni S; Tancini G
Int J Biol Markers; 1989; 4(4):203-6. PubMed ID: 2628500
[TBL] [Abstract][Full Text] [Related]
49. Plasma-soluble interleukin-2 and transferrin receptor in schizophrenia and major depression.
Maes M; Meltzer HY; Buckley P; Bosmans E
Eur Arch Psychiatry Clin Neurosci; 1995; 244(6):325-9. PubMed ID: 7772617
[TBL] [Abstract][Full Text] [Related]
50. The IL-2 - IL-2 receptor pathway in health and disease: The role of the soluble IL-2 receptor.
Damoiseaux J
Clin Immunol; 2020 Sep; 218():108515. PubMed ID: 32619646
[TBL] [Abstract][Full Text] [Related]
51. Evaluation of serum levels of tumour necrosis factor-alpha (TNF-alpha) and soluble IL-2 receptor (sIL-2R) and CD4, CD8 and natural killer (NK) populations during infrared pulsed laser device (IPLD) treatment.
Santana-Blank LA; Castes M; Rojas ME; Vargas F; Scott-Algara D
Clin Exp Immunol; 1992 Oct; 90(1):43-8. PubMed ID: 1395099
[TBL] [Abstract][Full Text] [Related]
52. Hyper-interleukin (IL)-6-naemia in haemophagocytic lymphohistiocytosis.
Imashuku S; Hibi S; Fujiwara F; Todo S
Br J Haematol; 1996 Jun; 93(4):803-7. PubMed ID: 8703806
[TBL] [Abstract][Full Text] [Related]
53. Soluble IL-2 alpha and ovarian cancer.
Barton DP
Br J Cancer; 1994 Mar; 69(3):622-3. PubMed ID: 8123502
[No Abstract] [Full Text] [Related]
54. Pathophysiology of the immune system in elderly subjects with or without diabetes and variations after recombinant interleukin-2.
Carnazzo G; Mirone G; Turturici A; Favetta A; Campo ME; Cosenza C; Chiarenza G; Stivala F
Arch Gerontol Geriatr; 1989; 9(2):163-80. PubMed ID: 2589917
[TBL] [Abstract][Full Text] [Related]
55. Stimulation of soluble interleukin-2 release by tumor necrosis factor-alpha in cancer patients.
Zubelewicz B; Braczkowski R; Rovelli F; Lissoni P; Pittalis S
Int J Biol Markers; 1995; 10(3):186-7. PubMed ID: 8551065
[No Abstract] [Full Text] [Related]
56. [Contribution to the clinical study of senile diabetes].
AZZOLINI G
G Gerontol; 1959 Dec; 7():904-7. PubMed ID: 13795435
[No Abstract] [Full Text] [Related]
57. Studies on senile diabetes.
ECKERSTROM S
Gerontol Clin (Basel); 1960; 2():210-26. PubMed ID: 13819216
[No Abstract] [Full Text] [Related]
58. [Cancer of a senile disease].
MARKOV VN
Izv Meditsinskite Inst Bulg Akad Naukite Sofia Otd Biol Meditsinski Nauki; 1952; 1(6-7):37-52. PubMed ID: 13044375
[No Abstract] [Full Text] [Related]
59. [Preliminary study on change of interleukin-2 and its receptor in the elderly].
Dong B; Zhou J; Wang Z
Hua Xi Yi Ke Da Xue Xue Bao; 1995 Sep; 26(3):342-4. PubMed ID: 8586407
[TBL] [Abstract][Full Text] [Related]
60. Serum interleukin-2 and soluble interleukin-2 receptor in gestational trophoblastic diseases.
Shaarawy M; Darwish NA; Abdel-Aziz O
J Soc Gynecol Investig; 1996; 3(1):39-46. PubMed ID: 8796806
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
